NCT01490983

Telemonitoring Study - for Chronic Myeloid Leukemia (CML)

Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Nilotinib) Therapy

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: Rex Cancer Center, Raleigh, NC · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is being conducted in a population of patients with chronic phase Chronic Myeloid Leukemia (CML) to learn more about how patients follow prescribed regimens for taking oral cancer drugs.

Detailed description

This is a randomized, controlled pilot study to introduce eMedonline telemonitoring technology to CML patients taking Gleevec or Tasigna. eMedonline will be used to automatically collect time-dose specific medication data for individual patients, including dosing times, missed doses, adverse events and e-diary data. All data will be available to research staff for remote review via Web interface. Adverse events and non-adherence will prompt interventions including supportive care counseling.

Conditions

• Chronic Myeloid Leukemia

Interventions

Type	Name	Description
BEHAVIORAL	no access to eMedonline	patients will be followed for 3 months but will not use eMedonline
BEHAVIORAL	eMedonline access	patients will be given access to eMedonline use for 3 months

Timeline

• Start date: 2009-04-01
• Primary completion: 2014-10-01
• Completion: 2014-12-01
• First posted: 2011-12-13
• Last updated: 2018-08-13

Locations

3 sites across 1 country: United States